Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | LLY Lilly (Eli) | ABT Abbott Laboratories |
|---|---|---|
| Price | $1,152.93 +0.0% | $102.61 +0.4% |
| StockIQ Score | 59C Moderate Risk: Medium | 51C- Moderate Risk: Medium |
| Technical | 38F | 19F |
| Fundamental | 70B | 72B |
| Growth | 74B | 45D+ |
| Fair Value | 45D+ | 38F |
| News | 98A+ | 100A+ |
| Quality | 50C- | 63C+ |
| Risk | 50C- | 54C- |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
LLY has a higher growth score (74 vs 45) and a higher valuation score (45 vs 38) than ABT. ABT edges out LLY in investor score (51 vs 50), fundamental score (72 vs 70), and both share the same technical score of 23. Overall, LLY leads on growth and valuation, while ABT is slightly stronger on investor and fundamentals.